(firstQuint)RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies.

 Bardoxolone methyl (RTA 402) is a synthetic triterpenoid that has demonstrated significant in vivo single agent anti-cancer activity.

 This is an open-label phase I dose-escalation study of Bardoxolone methyl (RTA 402) administered orally for the first 21 days of a 28-day cycle.

.

 RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies@highlight

This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.

